EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	18742	STAPPER.in. or GLOMBIK.in. or FALK. in. or GRETZKE.in. or GOERLITZER.in. or KEIL.in. or SCHAEFER.in. or "WENDLER.in. "	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 11:34
L2	45	l1 and alkanoic	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 11:34
L3	533	l1 and cycloalkyl	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 11:35
L4	124	l1 and "562"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 11:35
L5	320	l1 and "560"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 11:35
L6	378	l4 or l5	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 11:35
L7	25	l6 and l3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 11:35
L8	66	l2 or l7	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 12:25
L9	1779	562/400 or 562/498 or 562/503 or 562/505 or 562/506 or 562/507 or 562/508 or 562/510	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 12:26

EAST Search History

L10	855	l9 and cycloalkyl	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 12:27
L11	157	l9 and alkanoic	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 12:27
L12	53	l10 and alkanoic	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 12:45
L13	333	l10 and aliphatic	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	ON	2006/09/12 12:28

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptayvv1621

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUl 14	FSTA enhanced with Japanese patents
NEWS	14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:46:14 ON 12 SEP 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:46:24 ON 12 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7
DICTIONARY FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10789324-hetero-nh2.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,CH2,CH

G2 C,H,Cb,Cy,Ak

G3 NH,CH2,CH,Ak

G4 H,Me,CH2,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,Ak

G5 C,O,S,N,P

G6 A,Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:46:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2943 TO ITERATE

68.0% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

```
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        55607 TO    62113
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:47:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    60662 TO ITERATE

100.0% PROCESSED    60662 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.02

L3            0 SEA SSS FUL L1
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptayvv1621

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:50:35 ON 12 SEP 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:50:56 ON 12 SEP 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7
DICTIONARY FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10789324-broad.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,CH2,CH

G2 C,H,Cb,Cy,Ak

G3 NH,CH2,CH,Ak

G4 H,Me,CH2,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:51:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 987 TO ITERATE

100.0% PROCESSED 987 ITERATIONS 2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 17856 TO 21624
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI)
MF C28 H46 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI)
MF C27 H44 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full
FULL SEARCH INITIATED 09:52:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20614 TO ITERATE

100.0% PROCESSED 20614 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.01

L3 15 SEA SSS FUL L1

=> d scan 1-
'1-' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel- (9CI)
MF C27 H44 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties

PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl]heptylamino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI)
MF C26 H50 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl]heptylamino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel- (9CI)

MF C28 H52 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl]heptylamino]eth oxy]-α-ethyl-, (1R,3R)-rel- (9CI)
MF C28 H52 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel- (9CI)
MF C29 H46 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI)
MF C27 H44 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Valine, N-[[3-[2-[[(ethylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]cyclohexyl]carbonyl]- (9CI)
MF C25 H39 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl]heptylamino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI)
MF C27 H52 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Valine, N-[[3-[2-[heptyl[(phenylamino)carbonyl]amino]ethoxy]cyclohexyl]carbonyl]- (9CI)
MF C28 H45 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl]heptylamino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI)
MF C29 H54 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Valine, N-[[3-[2-[(2,2-dimethylpropyl)[(phenylamino)carbonyl]amino]ethoxy]cyclohexyl]carbonyl]- (9CI)
MF C26 H41 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.26	168.47

FILE 'CAPLUS' ENTERED AT 09:53:23 ON 12 SEP 2006

FILE COVERS 1907 - 12 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 11 Sep 2006 (20060911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 1 L3

=> d

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:738381 CAPLUS
DN 141:260284
TI Preparation of cis-3-hydroxy-cyclohexanebutanoic acids as PPAR agonists for the treatment of type II diabetes
IN Stapper, Christian; Glombik, Heiner; Falk, Eugen; Goerlitzer, Jochen; Gretzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Wendler, Wolfgang
PA Aventis Pharma Deutschland GmbH, Germany
SO Ger. Offen., 30 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10308356	A1	20040909	DE 2003-10308356	20030227
	AU 2004215678	A1	20040910	AU 2004-215678	20040219
	CA 2516633	AA	20040910	CA 2004-2516633	20040219
	WO 2004076401	A1	20040910	WO 2004-EP1587	20040219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1599443	A1	20051130	EP 2004-712498	20040219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007871	A	20060301	BR 2004-7871	20040219
	CN 1753865	A	20060329	CN 2004-80005473	20040219
	JP 2006519200	T2	20060824	JP 2006-501893	20040219
	US 2004220261	A1	20041104	US 2004-789324	20040227
	NO 2005004389	A	20051103	NO 2005-4389	20050922
PRAI	DE 2003-10308356	A	20030227		
	US 2003-487437P	P	20030715		
	WO 2004-EP1587	A	20040219		

OS MARPAT 141:260284
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.74	174.21

FILE 'REGISTRY' ENTERED AT 09:59:05 ON 12 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7
DICTIONARY FILE UPDATES: 11 SEP 2006 HIGHEST RN 906423-10-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10789324-hetero.str

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 C,O,CH2,CH

G2 C,H,Cb,Cy,Ak

G3 NH,CH2,CH,Ak

G4 H,Me,CH2,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,Ak

G5 C,O,S,N,P

Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 09:59:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2717 TO ITERATE

73.6% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 51214 TO 57466
PROJECTED ANSWERS: 2 TO 152

L6 2 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 09:59:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 55864 TO ITERATE

100.0% PROCESSED 55864 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.02

L7 24 SEA SSS FUL L5

=> d l7 scan

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenepropanoic acid, 4-[2-[[[(2,3-dichlorophenyl)amino]carbonyl](phenylmethyl)amino]ethyl]-α,α-dimethyl- (9CI)
MF C27 H28 Cl2 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Valine, N-[[3-[2-[[(ethylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]cyclohexyl]carbonyl]- (9CI)
MF C25 H39 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-

methylphenyl)methyl]amino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI)
MF C28 H46 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl]heptylamino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI)
MF C26 H50 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Alanine, N-[4-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenyl]-2-methyl- (9CI)
MF C26 H35 F2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Methionine, N-[[5-[2-[(cyclohexylmethyl)[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]ethyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]-(9CI)
MF C39 H53 N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel-(9CI)
MF C29 H46 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl]heptylamino]eth
oxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI)
MF C29 H54 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl][(4-
methylphenyl)methyl]amino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI)
MF C29 H46 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzenepropanoic acid, 4-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylam
ino]ethyl]-α,α-dimethyl- (9CI)

MF C27 H36 F2 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 24 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI)
MF C30 H48 N2 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.26	342.47

FILE 'CAPLUS' ENTERED AT 10:01:39 ON 12 SEP 2006

FILE COVERS 1907 - 12 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 11 Sep 2006 (20060911/ED)

=> s l7
L8 6 L7

=> d l8 abs ibib hitstr 1-
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AB Docking is a computational technique that samples conformations of small mols. in protein binding sites; scoring functions are used to assess which of these conformations best complements the protein binding site. An evaluation of 10 docking programs and 37 scoring functions was conducted against eight proteins of seven protein types for three tasks: binding mode prediction, virtual screening for lead identification, and rank-ordering by affinity for lead optimization. All of the docking programs were able to generate ligand conformations similar to crystallog. determined protein/ligand complex structures for at least one of the targets. However, scoring functions were less successful at distinguishing the crystallog. conformation from the set of docked poses. Docking programs identified active compds. from a pharmaceutically relevant pool of decoy compds.; however, no single program performed well for all of the targets. For prediction of compound affinity, none of the docking programs or scoring functions made a useful prediction of ligand binding affinity.

ACCESSION NUMBER: 2005:777848 CAPLUS
TITLE: A Critical Assessment of Docking Programs and Scoring Functions
AUTHOR(S): Warren, Gregory L.; Andrews, C. Webster; Capelli, Anna-Maria; Clarke, Brian; LaLonde, Judith; Lambert, Millard H.; Lindvall, Mika; Nevins, Neysa; Semus, Simon F.; Senger, Stefan; Tedesco, Giovanna; Wall, Ian D.; Woolven, James M.; Peishoff, Catherine E.; Head, Martha S.
CORPORATE SOURCE: GlaxoSmithKline Pharmaceuticals, Collegeville, PA, 19426, USA
SOURCE: Journal of Medicinal Chemistry ACS ASAP
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 865717-69-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(critical assessment of docking programs and scoring functions)

RN 865717-69-7 CAPLUS
CN Benzenepropanoic acid, 4-[2-[[[(2,3-dichlorophenyl)amino]carbonyl](phenylmethyl)amino]ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

II

AB Title compds. I [A = (un)substituted cycloalkandiyl (sic) ring, cycloalkendiyl (sic) ring; R1, R2 = H, alkyl, cycloalkyl, etc.; R3 = (un)substituted cycloalkyl, alkyl; R4 = alkyl; R5 = H, alkyl; R6 = H; X = alkandiyl (sic) with provisos; Y1 = CO; Y2 = NH, alkandiyl with provisos] and their pharmaceutically acceptable salts were prepared For example, TFA mediated deprotection of t-Bu ester II (Z = t-butyl), e.g., prepared from 3-allylcyclohexanone in 9-steps, afforded acid II (Z = H). In PPAR-α receptor binding assays, 7-examples of compds. I exhibited EC50 values ranging from 0.38-74 nM, e.g., the EC50 value of acid II (Z = H) was 1.1 nM. Compds. I are claimed useful for the treatment of type II diabetes.

ACCESSION NUMBER: 2004:738381 CAPLUS
DOCUMENT NUMBER: 141:260284
TITLE: Preparation of cis-3-hydroxy-cyclohexanebutanoic acids as PPAR agonists for the treatment of type II diabetes
INVENTOR(S): Stapper, Christian; Glombik, Heiner; Falk, Eugen; Goerlitzer, Jochen; Gretzke, Dirk; Keil, Stefanie;

Schaefer, Hans-Ludwig; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Ger. Offen., 30 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10308356	A1	20040909	DE 2003-10308356	20030227
AU 2004215678	A1	20040910	AU 2004-215678	20040219
CA 2516633	AA	20040910	CA 2004-2516633	20040219
WO 2004076401	A1	20040910	WO 2004-EP1587	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1599443	A1	20051130	EP 2004-712498	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007871	A	20060301	BR 2004-7871	20040219
CN 1753865	A	20060329	CN 2004-80005473	20040219
JP 2006519200	T2	20060824	JP 2006-501893	20040219
US 2004220261	A1	20041104	US 2004-789324	20040227
NO 2005004389	A	20051103	NO 2005-4389	20050922
PRIORITY APPLN. INFO.:			DE 2003-10308356 A	20030227
			US 2003-487437P P	20030715
			WO 2004-EP1587 A	20040219

OTHER SOURCE(S): MARPAT 141:260284
IT 754234-67-8P 754234-69-0P 754234-71-4P
754234-73-6P 754234-75-8P 754234-77-0P
754234-79-2P 754234-82-7P 754234-84-9P
754234-85-0P 754234-87-2P 754234-89-4P
754234-91-8P 754234-93-0P 754235-75-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cis-hydroxycyclohexanebutanoic acids as PPAR agonists for the treatment of type II diabetes)
RN 754234-67-8 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-69-0 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl]heptylamino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-71-4 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl]heptylamino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-73-6 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-ethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-75-8 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl]heptylamino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-77-0 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl]heptylamino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-79-2 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-82-7 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl]heptylamino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-84-9 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(butylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-85-0 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl]heptylamino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-87-2 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α,α-dimethyl-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754234-89-4 CAPLUS
CN L-Valine, N-[[3-[2-[[(ethylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754234-91-8 CAPLUS
CN L-Valine, N-[[3-[2-[heptyl[(phenylamino)carbonyl]amino]ethoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754234-93-0 CAPLUS
CN L-Valine, N-[[3-[2-[(2,2-dimethylpropyl)[(phenylamino)carbonyl]amino]ethoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754235-75-1 CAPLUS
CN Cyclohexanebutanoic acid, 3-[2-[[(cyclohexylamino)carbonyl][(4-methylphenyl)methyl]amino]ethoxy]-α-(1-methylethyl)-, (1R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I



II

AB Title compds. I and their prodrugs and/or pharmaceutically acceptable salts are claimed [wherein: E = CO, SO2; B = CH2, NH; Z = CO2H, CHO, CH2OH, alkoxycarbonyl, cyano, CONHOH, tetrazolyl, tetrazolylaminocarbonyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl, 3-oxo-isoxazolidin-4-ylaminocarbonyl, CONHSO2R4; R1 = H, alkyl, cycloalkyl; R2 = H, cycloalkyl, (un)substituted and/or (un)saturated (hetero)aliphatic chain; R3 = (un)substituted alk(en/yn)yl; R4 = alkyl, amino or its (di)((poly)fluoro)alkyl derivs.; R5, R6 = H, alkyl, cycloalkyl, or cycloalkylalkyl; or R5R6 = atoms to form 3- to 6-membered fully saturated carbocyclic ring; A = H, (di)(alkyl)amino, alkanoylamino, alkoxy, or (un)substituted (un)saturated (bi)(hetero)cyclic ring; W = bond, NH, N-alkyl, alkylamino (sic), or alkylene; or W = CR7R8 where R7R8 = atoms to form 3- to 6-membered fully saturated carbocyclic ring]. The compds. are disclosed as PPAR (peroxisome proliferator-activated receptor) agonists, and particularly as PPARα activators (no data). Also disclosed are pharmaceutical compns. containing I, and the use of I to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol, and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides, and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. Further claimed uses include treatment of obesity, diabetes and related conditions, atherosclerosis, hypertension, inflammation, and thrombosis. The compds. may also be administered in combination with a variety of other enzyme inhibitors. A total of 77 synthetic examples cover production of various I and their intermediates. The (R)- and (S)-enantiomers of approx. 15 compds. are specifically claimed. For instance, [4-(2-heptylaminoethyl)phenyl]methanol (preparation in 3 steps given) underwent a sequence of: (1) N-protection with BOC, (2) O-oxidation with MnO2 to an aldehyde, (3) Wittig type reaction of the latter with Ph2P(:O)CH(OEt)CO2Et, (4) reduction of the resultant acrylate ester to a propionate ester, (5) removal of BOC, (6) carbamoylation with 2,4-dimethoxyphenyl isocyanate, and (7) alkaline hydrolysis of the Me ester, to give title compound II.

ACCESSION NUMBER: 2002:637640 CAPLUS
DOCUMENT NUMBER: 137:185320
TITLE: PPAR agonists, e.g., 3-[4-[2-[3-(2,4-dimethoxyphenyl)-1-heptylureido]ethyl]phenyl]-2-ethoxypropionic acid and analogs, useful particularly as PPARα agonists, and their pharmaceutical compositions and therapeutic use as hypolipemics, antidiabetics, etc.
INVENTOR(S): Hayward, Cheryl Myers; Perry, David Austen

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064549	A1	20020822	WO 2002-IB45	20020107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438551	AA	20020822	CA 2002-2438551	20020107
EP 1360172	A1	20031112	EP 2002-740089	20020107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007285	A	20040210	BR 2002-7285	20020107
JP 2004529097	T2	20040924	JP 2002-564482	20020107
US 2002165282	A1	20021107	US 2002-76740	20020214
US 6699904	B2	20040302		

PRIORITY APPLN. INFO.: US 2001-269058P P 20010215
WO 2002-IB45 W 20020107

OTHER SOURCE(S): MARPAT 137:185320

IT 449201-44-9P, 3-[4-[2-[3-(2,4-Difluorophenyl)-1-heptylureido]ethyl]phenyl]-2,2-dimethylpropionic acid 449201-56-3P, 2-[[4-[2-[3-(2,4-Difluorophenyl)-1-heptylureido]ethyl]phenyl]amino]-2-methylpropionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of [[[(dimethoxyphenyl)heptylureido]ethyl]phenyl]ethoxypropionic acid and analogs as PPAR agonists)

RN 449201-44-9 CAPLUS
CN Benzenepropanoic acid, 4-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 449201-56-3 CAPLUS
CN Alanine, N-[4-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AB 3-AWEN(CH2R3)12CR5R6C6H4BCR1R2Z [A = H, (un)substituted NH2, alkoxy, aryl, cycloalkyl, heterocyclic; W = bond, (un)substituted NH, azaalkylene, alkylene, cycloalkylene; E = CO, SO2; B = O, S, S(O), SO2, CH2, NH; Z = CO2H, CHO, CH2OH, alkoxycarbonyl, CN, CONHOH, tetrazolyl, tetrazolylaminocarbonyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl, 3-oxoisoxazolidin-4-ylaminocarbonyl, CONHSO2R4; R1 = H, alkyl, cycloalkyl; R2 = H, cycloalkyl, (un)substituted alkyl; R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = (un)substituted alkyl, NH2; R5, R6 = H, alkyl, cycloalkyl, cycloalkylalkyl; CR5R6 = carbocyclic] were prepared for use as PPARα activators (no data). These compds. elevate certain plasma lipid levels, including HDL-cholesterol and lower certain plasma lipid levels, such as LDL-cholesterol and triglycerides and are used to treat diseases which are exacerbated by low levels of HDL-cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. Thus, 3-MeOC6H4CH2CH2NH2 was demethylated, converted to the amide with heptanoic acid, and treated with Cl3CCMeEtOH to give 3-Me(CH2)5CONHCH2CH2C6H4OCMeEtCO2H which was converted to the benzyl ester and reduced to 3-Me(CH2)6NHCH2CH2C6H4OCMeEtCO2CH2Ph. This ester was treated with 2,4-F2C6H3NCO and debenzylated to give 3-Me(CH2)6N(CONHC6H3F2-2,4)CH2CH2C6H4OCMeEtCO2H.

ACCESSION NUMBER: 2002:637514 CAPLUS
DOCUMENT NUMBER: 137:185319
TITLE: Phenoxyalkanoic acids as peroxisome proliferator activator receptor (PPARα) agonists
INVENTOR(S): Hayward, Cheryl Myers; Perry, David Austen
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064130	A1	20020822	WO 2002-IB43	20020109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438492	AA	20020822	CA 2002-2438492	20020109
EP 1372632	A1	20040102	EP 2002-740088	20020109

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2002007227	A	20040210	BR 2002-7227		20020109
JP 2004520397	T2	20040708	JP 2002-563924		20020109
US 2002169192	A1	20021114	US 2002-76318		20020214
US 2005075377	A1	20050407	US 2004-955098		20040929
PRIORITY APPLN. INFO.:			US 2001-269057P	P	20010215
			WO 2002-IB43	W	20020109
			US 2002-76318	B3	20020214

OTHER SOURCE(S): MARPAT 137:185319

IT 450413-13-5P 450413-14-6P 450413-15-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenoxyalkanoic acids as peroxisome proliferator activator receptor (PPARα) agonists)

RN 450413-13-5 CAPLUS
CN Alanine, N-[3-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 450413-14-6 CAPLUS
CN Alanine, N-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]ethyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 450413-15-7 CAPLUS
CN Alanine, N-[3-[2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]heptylamino]ethyl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is L4NR5L5 where L4 and L5 are absent or alkylene, R5 is H, alkanoyl, alkoxy, alkoxyalkyl, haloalkyl, etc.; Z is a covalent bond; R3 =

cycloalkyl, alkoxy, alkyl, halogen, oxo, etc.] or their pharmaceutically acceptable salts, were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-[(R)-thiazolidin-4-ylcarbonylamino]-2-phenylbenzoyl]methionine Me ester hydrochloride, prepared via amidation reaction, showed 92% inhibition of farnesyl transferase at 1x10-6 M.

ACCESSION NUMBER: 2001:792340 CAPLUS
DOCUMENT NUMBER: 135:331672
TITLE: Preparation of methionine derivatives as inhibitors of protein isoprenyl transferases
INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; O'connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorenson, Bryan K.; Sullivan, Gerard M.; Tasker, Andrew S.; Wasicak, James T.; Nelson, Lissa T. J.; Henry, Kenneth J.; Wang, Le
PATENT ASSIGNEE(S): University of Pittsburgh, USA
SOURCE: U.S., 514 pp., Cont.-in-part of U.S. Ser. No. 852,858, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6310095	B1	20011030	US 1998-73794		19980507
ZA 9906763	A	20000515	ZA 1999-6763		19991027
PRIORITY APPLN. INFO.:			US 1995-7247P	P	19951106
			US 1996-740909	B2	19961105
			US 1997-852858	B2	19970507
			US 1998-73794	A	19980507
			US 1998-197279	A	19981120

OTHER SOURCE(S): MARPAT 135:331672
IT 216230-73-8P 216233-47-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of methionine derivs. as inhibitors of protein isoprenyl transferases)
RN 216230-73-8 CAPLUS
CN L-Methionine, N-[[5-[[(2-cyclohexylethyl)[(dimethylamino)carbonyl]amino]methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216233-47-5 CAPLUS
CN L-Methionine, N-[[5-[2-[(cyclohexylmethyl)[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]ethyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]-,

monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AB Compds. R3-Z-L1-aryl [aryl is a benzene ring having certain substituents R1, R2, R4; L1 is absent or is L4NR5L5, L4OL5, L4S(O)mL5 (m = 0-2), etc., where L4 and L5 are absent or alkylene, alkenylene, R5 is H, alkanoyl; Z is a covalent bond, O, S(O)q (q = 0-2), NH or imino; R3 = H, aryl, fluorenyl, heterocyclyl, cycloalkyl, etc.] were prepared as inhibitors of protein isoprenyl transferases. Thus, N-[4-[(R)-thiazolidin-4-ylcarbonylamino]-2-phenylbenzoyl]methionine Me ester hydrochloride, prepared via amidation reaction, showed 92% inhibition of farnesyl transferase at 1x10-6 M.

ACCESSION NUMBER: 1998:744940 CAPLUS
DOCUMENT NUMBER: 130:25338
TITLE: Inhibitors of protein isoprenyl transferases
INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Augeri, David J.; Barr, Kenneth J.; Donner, Bernard G.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce G.; Tasker, Andrew S.; Wasick, James I.; Winn, Martin
PATENT ASSIGNEE(S): University of Pittsburgh, USA
SOURCE: PCT Int. Appl., 848 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850029	A1	19981112	WO 1998-US9296	19980507

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,

VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2288330	AA	19981112	CA 1998-2288330		19980507
AU 9874733	A1	19981127	AU 1998-74733		19980507
EP 986384	A1	20000322	EP 1998-922122		19980507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2002518985	T2	20020625	JP 1998-548480		19980507
TW 492955	B	20020701	TW 1998-87107182		19980715
TW 541302	B	20030711	TW 1998-87107183		19980715
MX 9910186	A	20000630	MX 1999-10186		19991105
PRIORITY APPLN. INFO.:			US 1997-852858	A	19970507
			WO 1998-US9296	W	19980507

OTHER SOURCE(S): MARPAT 130:25338

IT 216230-73-8P 216233-47-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of inhibitors of protein isoprenyl transferases)

RN 216230-73-8 CAPLUS
CN L-Methionine, N-[[5-[[(2-cyclohexylethyl)[(dimethylamino)carbonyl]amino]methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216233-47-5 CAPLUS
CN L-Methionine, N-[[5-[2-[(cyclohexylmethyl)[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]ethyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT